Home › NCT03869814
Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types
RecruitingObservational studyHealthy volunteers welcome
Who can join
Ages 21 to 80 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria 1. Subjects must be between 21-80 years of age at the time of enrollment 2. Patient fully consented 3. Cancer diagnosis OR high clinical suspicion for cancer, based on the participating site's and practitioner's standards of care (SOC) 4. No previous history of cancer and treatment naïve at time of enrollment Exclusion Criteria 1. Age \< 21 OR \> 80 years of age 2. Any prior cancer diagnosis with or without treatment (with the exception of non-melanoma skin cancers resolved/treated \> 1 year prior to enrollment) 3. Receipt of any cancer therapy including chemotherapy, radiation, palliative radiation, hormonal or naturopathic therapies 4. In situ carcinoma without an invasive component 5. Any surgery requiring general anesthesia within 2 months of collection. Anesthesia used in procedures such as colonoscopy and EBUS is acceptable. 6. Receipt of systemic immunomodulation therapy within past 12 months 7. Currently pregnant, or pregnancy within last 12 months 8. Organ transplantation 9. Received dialysis 10. Blood transfusion within 1 month 11. Known HIV/AIDs, Hepatitis A, D, or E, TB, any kind of prion disorder (e.g., CJD) or other infectious pathogens currently present or present in past 5 years.
About the study
ClearNote Health is developing a test from whole blood for the early detection of multiple cancers. The goal of this study is to employ genomics, epigenomics and proteomics methodology for the detection of cancer signal in the blood of subjects with solid tumors.
What is being tested
- Blood Draw (other)
Sponsor: ClearNote Health · Participants: 20,000 · Started: Apr 5, 2018
Contact the study team
- Melissa Peters, MA, PMP, CCRC · Phone: 619-277-2160
Official record on ClinicalTrials.gov — NCT03869814
Locations in the U.S.
| California | ClearNote Health, Inc., San Diego |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.